TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1-6 infection.~* Positive plasma HCV antibody and HCV RNA viral load greater than or equal to 1000 IU/mL at Screening.~* Treatment-naive to any approved or investigational anti-HCV medication.~* Participant must be documented as cirrhotic, with a Child-Pugh score of less than or equal to 6.~Exclusion Criteria:~* Female participant who is pregnant, breastfeeding or is considering becoming pregnant during the study, or for approximately 30 days after the last dose of study drug.~* Any current or historical clinical evidence of decompensated cirrhosis.~* Positive test result at Screening for hepatitis B surface antigen (HBsAg), HBV deoxyribonucleic acid \> lower limit of quantification (LLOQ) in subjects with isolated positive antibody to hepatitis B core antigen (anti-HBc) (i.e., negative HBsAg and anti-hepatitis B),or anti human immunodeficiency virus antibody (HIV Ab).~* HCV genotype performed by the central laboratory during screening indicating co-infection with more than one HCV genotype.~* History of suspected or confirmed hepatocellular carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks (Type: EXPERIMENTAL): Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years inclusive on study day 1. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for ≥ 1 year (with follicle-stimulating hormone \[FSH\] ≥ 38 mIU/mL) and must have a negative serum pregnancy test result before administration of test article.~2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥ 50 kg.~3. Healthy as determined by the investigator on the basis of screening evaluations.~Exclusion criteria:~1. Family history QT prolongation, syncope, seizure, or unexplained cardiac related death.~2. Presence or history of any disorder that may prevent the successful completion of the study.~3. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Between Colchicine and Ritonavir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults 18-45 years of age, non-smoking and non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) with a body mass index (BMI) greater than or equal to 18 and less than or equal to 32, inclusive.~Exclusion Criteria:~* Recent participation (within 28 days) in other research studies~* Recent significant blood donation or plasma donation~* Pregnant or lactating~* Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)~* Recent (2-year) history or evidence of alcoholism or drug abuse~* History or presence of significant cardiovascular, hyperlipidemia, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease~* Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Colchicine alone (Type: ACTIVE_COMPARATOR): -baseline colchicine pharmacokinetics
- Colchicine with Ritonavir (Type: EXPERIMENTAL): -colchicine pharmacokinetics in presence of steady-state ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CKD-11101 Phase 3 SC Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria~  1. Patients with 19 years of age or older~ 2. Patients with chronic renal failure of stage 3 or above who are not on dialysis~ 3. Patients with the Hb levels of 8 to 10g/dl measured at screening~ 4. Patients with enough body iron stores who meet the following item:~     -Serum ferritin ≥ 100ng/ml or Transferrin saturation ≥ 20%~ 5. Patients who have provided written consent to participate in the clinical trial voluntarily~* Exclusion Criteria~  1. Patients who are expected to need dialysis within a year or patients with rapidly progressive chronic renal failure~ 2. Patients who have received drug treatment such as erythropoiesis stimulating agent for the purpose of correcting anemia within 12 weeks prior to screening~ 3. Patients who have received red blood cell transfusion within 12 weeks prior to screening~ 4. Patients with uncontrolled hypertension~ 5. Patients who had hypersensitivity to erythropoietin agents~ 6. Patients who had known hypersensitivity to mammalian cell-derived products or additives~ 7. Patients with history of severe cardiovascular diseases~ 8. Patients whose anemia is not caused by chronic renal failure or may affect anemia correction including the following conditions:~ 9. Patients whose AST/ALT test results performed at screening exceeds twice of normal upper limit~ 10. Patients who have experience of positive result in anti-erythropoietin antibody in previous treatment with erythropoiesis stimulating agent

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CKD-11101(Darbepoetin alfa) (Type: EXPERIMENTAL): The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
- NESP(Darbepoetin alfa) (Type: ACTIVE_COMPARATOR): The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females.~* Age more than 18 and below 80 years.~* Patients with stable CAD planned for elective PCI.~* Thienopyridine naive for at least two weeks before admission.~Exclusion Criteria:~* Pregnant~* Any urgent/emergent coronary angiography procedure that would not allow for genetic testing to be performed before PCI~* Considered at high risk for bleeding~* History of ischemic or hemorrhagic stroke or transient ischemic attack~* . Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin~* History of ACS within 12 months of screening or need for revascularization~* Any acute or chronic unstable condition.~* Liver disease.~* Have increased bleeding risk, e.g., recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count.~* History of intolerance or allergy to ticagrelor or clopidogrel~* Patient on dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19\*2 or \*3 allele carriers.
- Ticagrelor (Type: EXPERIMENTAL): The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19 CYP2C19\*2 or \*3 allele carriers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥6months to ≤35 months-old healthy children (male or female) born at term after normal pregnancy~* Recording of medical history and physical examination reveal no abnormality~* The parent/legal guardian of the participating child must sign the written informed consent and agree to provide a blood sample taken from the child pre- and post-immunization~Exclusion criteria:~* Hypersensitivity to eggs, chicken proteins, polymyxin B, neomycin or any component of the vaccine~* Previous vaccination against influenza~* At time of enrollment, presentation of clinical symptoms of active infection and/or body temperature ≥38°C~* Confirmation or suspicion of immunosuppressed status (including cancer), or confirmation of immunodeficiency disease (congenital or acquired including HIV)~* Medical treatment (\>2 weeks) with immune suppressant or immune modulating drugs including systemic steroids during the last 3 months before immunization or at present, as follows: long-term oral prednisone or other equivalent steroid: ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the study is allowed)~* Treatment with immunoglobulins or blood products during the last 3 months before immunization or such treatment scheduled during the study~* Participation in other clinical trials during the last 3 months before immunization or intention to participate during this study period~* At present or during the last 6 months before immunization: radiotherapy or treatment with cytotoxic drugs~* Other vaccination with a killed vaccine within 14 days before immunization or with an attenuated vaccine within 28 days before immunization (note: after subject inclusion vaccines of the immunization program for children are allowed upon the physician's discretion. However, immunization on the same day must be avoided)~* Family history of Guillain-Barré Syndrome~* Severe congenital deficiency or disease~* Antecedent of neurological disease or epileptic attack~* Severe cardiopulmonary disease with possibility to influence the study result~* Disturbance of coagulation or under anticoagulant treatment, likely to be contraindicated to i.m. injection~* Suspected non-compliance

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Inflexal 0.5 mL (Type: EXPERIMENTAL): None
- Inflexal 0.25 mL (Type: EXPERIMENTAL): None
- Agrippal 0.25 mL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 30 years of age or older.~2. Subjects who have the clinical diagnosis of probable AD (30) ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR), cognitive normal elderly (30) age \>60 and cognitive normal young subjects (30) ages 30-60.~3. Normal subjects with Clinical Dementia Rating (CDR) 0-0.5 and AD subjects with CDR of 0.5 or greater.~Exclusion Criteria:~1. Subjects unable to lie down without moving for 30 minutes.~2. Women who are pregnant or who cannot stop breast feeding for 24 hours.~3. Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc,.~4. Subjects who are too claustrophobic to perform the tests.~5. Subject who have had previous brain irradiation, stroke or brain tumor(s)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Alzheimer's Disease (Type: EXPERIMENTAL): Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
- Cognitive Normal Elderly (Type: ACTIVE_COMPARATOR): Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
- Cognitive Normal Young (Type: ACTIVE_COMPARATOR): Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with acute otitis media~Exclusion Criteria:~* Amoxicillin allergy~* Tympanic membrane perforation~* Tympanostomy tubes (current)~* Complication of acute otitis media such as mastoiditis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Amoxicillin-clavulanate (Type: EXPERIMENTAL): Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Semi-occluded Mask in the Treatment of Patients With Voice Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 60~* diagnosed with vocal fold lesion or polyp or cyst or atrophy or other voice condition (such as muscle tension dysphonia)~* recommended for voice therapy as treatment for voice disorder~Exclusion Criteria:~* Current smoker (greater than 5 cigarettes/week)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Voice Disorder Requiring Voice Therapy (Type: OTHER): Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 75 years of age , with ≥ 40Kg~* Histological or cytological confirmed colorectal cancer~* ECOG performance status of 0-1~* Standard regimen failed or no standard regimen available~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* - Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Evidence of CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: ACTIVE_COMPARATOR): treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
- control arm (Type: PLACEBO_COMPARATOR): control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Stable CKD patients who are currently on hemodialysis three times a week for at least 12 weeks prior to the acquisition of informed consent~* Patients on stable dose(s) of phosphate binder(s) for at least 28 days prior to the acquisition of informed consent.~* Patients on stable dose(s) of Vitamin D or calcitonin agent for at least 28 days prior to the acquisition of informed consent, in case patients are treated by those agents~Exclusion Criteria:~* History of major gastrointestinal surgery, or swallowing disorders, bowel obstruction, hemorrhagic gastrointestinal lesion~* Continuous severe constipation/diarrhea.~* History of parathyroid intervention \[parathyroidectomy（PTx），percutaneous ethanol injection therapy（PEIT）etc.\] within 1 year of the acquisition of informed consent~* Diet restriction such as fasting and/or excessive dieting~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASP1585 dose #1 (Type: EXPERIMENTAL): None
- ASP1585 dose #2 (Type: EXPERIMENTAL): None
- ASP1585 dose #3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Sevelamer hydrochloride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete